Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Trial Profile

Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs AUTO 1 (Primary)
  • Indications Burkitt's lymphoma; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARPALL
  • Most Recent Events

    • 15 Oct 2018 Planned number of patients changed from 18 to 32.
    • 15 Oct 2018 Planned End Date changed from 1 Dec 2028 to 1 Dec 2030.
    • 15 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top